Major Depressive Disorder Market Report 2023-2032: Market Size, Growth Drivers And Key Trends

The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company's Major Depressive Disorder Global Market Report 2023 identifies substance abuse and alcohol as the major driver for the Major Depressive Disorder market's growth in the forecast period. Substance and alcohol abuse are terms used to describe patterns of excessive and harmful use of substances, including alcohol, that can lead to negative physical, psychological and social consequences. It commonly co-occurs with major depressive disorder and both conditions tend to feed off each other and significantly increase the risk of physical and mental harm.
The major depressive disorder market size has grown steadily in recent years. It will grow from $5.96 billion in 2023 to $6.12 billion in 2024 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to pharmaceutical advances, mental health awareness, psychological therapies, public health initiatives.

The major depressive disorder market size is expected to see steady growth in the next few years. It will grow to $6.84 billion in 2028 at a compound annual growth rate (CAGR) of 2.8%.
Download Free Sample Of Major Depressive Disorder Market Report -
https://www.thebusinessresearchcompany.com/sample_request?id=13042&type=smp

Major competitors in the Major Depressive Disorder market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company.
A key trend in the Major Depressive Disorder market includes innovative products. Drug approvals for major depressive disorder treatment, such as VRAYLAR (cariprazine), are increasing due to the need for more effective and safer treatments. For instance, in December 2022, AbbVie Inc., a US-based pharmaceutical company, received approval for VRAYLAR (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults from the Food and Drug Administration (FDA), a US-based federal agency. VRAYLAR is an innovative atypical antipsychotic medication that balances dopamine and serotonin levels in the brain. It is the first atypical antipsychotic to be approved as an adjunctive treatment for major depressive disorder. Additionally, it is available in capsule form and is taken once daily.

Read More On The Global Major Depressive Disorder Market Report Here:
https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

The Major Depressive Disorder market is segmented -
• By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments
• By Diagnosis: Physical Examinations, Laboratory Tests, Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5), Other Diagnosis
• By End-User: Clinics, Hospitals, Other End-Users
• By Geography: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. North America was the largest region in the Major Depressive Disorder market.

The Business Research Company's "Global Major Depressive Disorder Market Report 2023" provides a thorough understanding of the market across 60 geographies. The report covers market size, growth rate, segments, drivers and trends in every region and country. In addition, the report offers insights on historical and forecast growth, helping players analyze and strategize better.

Explore Buying Options For The Major Depressive Disorder Market Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13042

The Table Of Content For The Major Depressive Disorder Market Include:
1. Executive Summary
2. Major Depressive Disorder Market Characteristics
3. Major Depressive Disorder Market Trends And Strategies
4. Major Depressive Disorder Market - Macro Economic Scenario
5. Global Major Depressive Disorder Market Size and Growth
……
26. South America Major Depressive Disorder Market
27. Brazil Major Depressive Disorder Market
28. Middle East Major Depressive Disorder Market
29. Africa Major Depressive Disorder Market
30. Major Depressive Disorder Market Competitive Landscape And Company Profiles

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.